Press Releases
LANXESS disinfectant kills coronavirus SARS-CoV-2 in just 60 seconds
Rely+On Virkon broad spectrum disinfectant, produced by specialty Chemicals Company LANXESS, demonstrates extremely rapid efficacy against the SARS-CoV-2 virus.
This is the finding of a recent study LANXESS commissioned through independent analysis laboratory Microbac Laboratories, Inc. in accordance with the...
Drug Research
Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration
Gilead Sciences, Inc. and Tango Therapeutics announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer.
Under the expanded multi-year collaboration, which builds on an agreement signed in...
Press Releases
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launched to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.
With...
Press Releases
OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT
OSE Immunotherapeutics announced the online publication in BioRxiv of positive data from preclinical and human ex vivo studies with CoVepiT, its prophylactic vaccine program based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against...
Press Releases
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine. Building on the existing agreement with Europe’s Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the...
Drug Research
Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization (CDMO) focused...
Clinical Trials
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, announced that the first participant has been dosed in its...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read